Immunological and Inflammatory Disorders
The sponsor maintains a comprehensive research portfolio addressing immune-mediated conditions affecting multiple organ systems. Investigation encompasses rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, exploring various therapeutic interventions including JAK inhibitors and TNF-alpha inhibitors. Research extends to inflammatory bowel diseases, specifically Crohn’s disease and ulcerative colitis, examining both induction and maintenance treatment strategies.
- Rheumatic and Musculoskeletal Diseases
- Dermatological Immune Conditions
- Gastrointestinal Inflammatory Pathologies
- Systemic Autoimmune Disorders
Studies evaluate disease activity measures, structural damage progression, and patient-reported outcomes across diverse populations, including treatment-naïve patients and those with inadequate responses to conventional therapies. The research incorporates radiographic progression assessment and biomarker analysis to understand therapeutic mechanisms.
Oncological Research
The organisation conducts extensive investigations in haematological malignancies and solid tumours. Research focuses on chronic lymphocytic leukaemia, follicular lymphoma, mantle cell lymphoma, and acute myeloid leukaemia, examining targeted therapies including BCL-2 inhibitors and BTK inhibitors. Studies explore combination regimens with chemotherapy, immunotherapy, and novel targeted agents.
- Haematological Malignancies
- Solid Tumour Investigations
- Combination Oncology Therapies
- Minimal Residual Disease Assessment
The research programme evaluates progression-free survival, overall survival, and complete response rates across various cancer types. Investigations include treatment strategies for relapsed or refractory disease, first-line therapies, and maintenance approaches following initial treatment success.
Neurological and Psychiatric Conditions
The sponsor pursues research addressing central nervous system disorders with significant unmet medical needs. Studies investigate Parkinson’s disease, examining motor and non-motor symptoms, dyskinesia, and disease progression. Research extends to major depressive disorder, exploring novel therapeutic mechanisms and treatment-resistant populations.
- Movement Disorders
- Mood and Affective Disorders
- Neurodegenerative Conditions
- Cognitive Function Assessment
Investigations employ validated rating scales including UPDRS for motor function assessment and MADRS for depression severity. Research encompasses both symptomatic management and potential disease-modifying approaches, with particular attention to quality of life improvements and functional outcomes.
Dermatological Conditions
The research portfolio includes substantial investment in inflammatory skin diseases, particularly atopic dermatitis, psoriasis, and hidradenitis suppurativa. Studies evaluate systemic therapies, topical treatments, and combination approaches targeting various inflammatory pathways. Research addresses both adult and paediatric populations across different disease severities.
- Chronic Inflammatory Skin Diseases
- Pruritus and Symptom Management
- Skin Barrier Function
- Disease Severity Assessment Tools
Investigations utilise standardised outcome measures including EASI scores, PASI scores, and IGA assessments to evaluate treatment efficacy. Research explores long-term safety profiles, quality of life impacts, and therapeutic responses in patients with prior treatment failures or contraindications to existing therapies.
Hepatological and Renal Disorders
The sponsor conducts research in chronic liver diseases, with emphasis on chronic hepatitis C and its complications. Studies examine antiviral therapies, treatment durations, and outcomes in diverse patient populations including those with cirrhosis and hepatocellular carcinoma. Research extends to IgA nephropathy, investigating disease progression and therapeutic interventions.
- Viral Hepatitis Management
- Chronic Kidney Diseases
- Liver Fibrosis and Cirrhosis
- Sustained Virological Response
Investigations assess SVR rates, proteinuria reduction, and long-term organ function preservation. Research incorporates real-world evidence studies and registry-based investigations to complement controlled clinical trials, examining treatment outcomes across various demographic and clinical subgroups.
